Published in Neuroscience on April 24, 2013
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med (2014) 4.21
The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment. Ann Gen Psychiatry (2016) 1.40
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. Curr Addict Rep (2014) 0.87
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend (2015) 0.87
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol (2015) 0.85
Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and Caffeine. Subst Abuse (2013) 0.85
Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther (2014) 0.83
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med (2015) 0.79
Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Neuropsychopharmacology (2017) 0.78
Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. Drug Alcohol Depend (2014) 0.78
Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. Pharmacogenomics J (2015) 0.77
Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend (2015) 0.77
Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology (2015) 0.77
Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Behav Pharmacol (2016) 0.77
Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature. Front Pharmacol (2016) 0.75
Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy. Pharmacogenomics (2014) 0.75
Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther (2017) 0.75
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend (2016) 0.75
Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. PLoS One (2017) 0.75
Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Devel Ther (2014) 0.75
Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review. CNS Drugs (2016) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 7.78
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev (2003) 6.09
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 4.79
Endocannabinoid signaling in the brain. Science (2002) 4.28
The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs (2003) 3.91
The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci (2009) 3.67
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) (1995) 3.61
Molecular and cellular basis of addiction. Science (1997) 3.57
Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33
Cannabis use and mental health in young people: cohort study. BMJ (2002) 3.26
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
The economic costs of heroin addiction in the United States. Drug Alcohol Depend (2001) 2.90
Neuroendocrine pharmacology of stress. Eur J Pharmacol (2003) 2.77
Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction (2003) 2.75
Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A (1987) 2.48
Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci (1981) 2.45
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther (2002) 2.18
There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology (2006) 2.17
Endocannabinoids. Eur J Pharmacol (1998) 2.17
The risks for late adolescence of early adolescent marijuana use. Am J Public Health (1999) 2.17
Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry (1998) 2.15
Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry (2001) 2.13
Opiate receptor: autoradiographic localization in rat brain. Proc Natl Acad Sci U S A (1976) 2.01
Molecular neurobiology of addiction. Am J Addict (2001) 1.97
Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol (2005) 1.96
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
Early adolescent marijuana use: risks for the transition to young adulthood. Psychol Med (2002) 1.88
Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res (1991) 1.88
Molecular mechanisms of drug addiction. J Neurosci (1992) 1.88
Cannabinoid signalling. Life Sci (2005) 1.83
mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci (2002) 1.81
Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci (2001) 1.78
The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs (2005) 1.75
The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science (1986) 1.75
Health aspects of cannabis. Pharmacol Rev (1986) 1.74
Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav (2005) 1.69
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 1.63
Cannabinoid receptors: where they are and what they do. J Neuroendocrinol (2008) 1.63
Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (2004) 1.59
Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J Chem Neuroanat (1995) 1.56
Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain (2006) 1.56
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction (1998) 1.56
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol (2005) 1.55
Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res (1983) 1.54
Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology (2006) 1.52
Neural substrates of opiate withdrawal. Trends Neurosci (1992) 1.52
Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend (1998) 1.52
Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat. J Comp Neurol (1996) 1.50
Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol (1999) 1.50
Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci (1999) 1.49
The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend (2001) 1.46
Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.44
The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci (1990) 1.42
CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci (1997) 1.38
Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience (2004) 1.36
Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther (1978) 1.36
Retrograde signaling by endocannabinoids. Curr Opin Neurobiol (2002) 1.36
Synergistic interactions between cannabinoid and opioid analgesics. Life Sci (2004) 1.35
Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc Natl Acad Sci U S A (1987) 1.34
Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci (1990) 1.34
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther (2001) 1.33
A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol (2005) 1.33
The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol (2005) 1.31
The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci (1993) 1.30
The pharmacological treatment of opioid addiction--a clinical perspective. Eur J Clin Pharmacol (2010) 1.30
Separation of mu-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. J Neurosci (2006) 1.30
Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther (1992) 1.29
Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci (1991) 1.28
Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm (2009) 1.28
Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev (2008) 1.27
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol (2010) 1.25
Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry (1999) 1.25
Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res (2008) 1.25
Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) (2003) 1.24
Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav (2005) 1.22
Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis (1993) 1.22
Molecular biology of opioid analgesia. J Pain Symptom Manage (2005) 1.21
Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev (1997) 1.21
Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am J Psychiatry (2005) 1.18
Morphine-Induced mu-opioid receptor desensitization. Mol Pharmacol (2005) 1.18
Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann N Y Acad Sci (2004) 1.17
Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry (2009) 1.16
Marijuana use and treatment outcome among opioid-dependent patients. Addiction (1998) 1.16
The burden of the nonmedical use of prescription opioid analgesics. Pain Med (2009) 1.14
Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol (2005) 1.14
Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol (2005) 1.13
Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res (2005) 1.13
Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry (2010) 1.60
Functional coupling between neurons and glia. J Neurosci (2000) 1.40
Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis (1993) 1.22
Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res (2005) 1.13
Evidence for regional heterogeneity in corticotropin-releasing factor interactions in the dorsal raphe nucleus. J Comp Neurol (2001) 1.09
Elk-1 associates with the mitochondrial permeability transition pore complex in neurons. Proc Natl Acad Sci U S A (2006) 1.04
Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.04
Corticotropin-releasing factor is preferentially colocalized with excitatory rather than inhibitory amino acids in axon terminals in the peri-locus coeruleus region. Neuroscience (2001) 1.03
Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents. J Comp Neurol (2008) 1.01
Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav (2007) 0.97
Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neuroscience (2007) 0.96
Increased vulnerability of the brain norepinephrine system of females to corticotropin-releasing factor overexpression. Mol Psychiatry (2012) 0.95
Work organization and low back pain in nursing personnel. Ergonomics (1987) 0.95
Amygdalar peptidergic circuits regulating noradrenergic locus coeruleus neurons: linking limbic and arousal centers. Exp Neurol (2011) 0.95
Cellular interactions between axon terminals containing endogenous opioid peptides or corticotropin-releasing factor in the rat locus coeruleus and surrounding dorsal pontine tegmentum. J Comp Neurol (2003) 0.94
Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. Gene Ther (2006) 0.94
Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res (2009) 0.90
Robust enkephalin innervation of the locus coeruleus from the rostral medulla. J Neurosci (1992) 0.90
Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett (2007) 0.89
Anatomical evidence for multiple pathways leading from the rostral ventrolateral medulla (nucleus paragigantocellularis) to the locus coeruleus in rat. Neurosci Lett (1990) 0.88
Ultrastructural evidence for co-localization of dopamine D2 and micro-opioid receptors in the rat dorsolateral striatum. Anat Rec A Discov Mol Cell Evol Biol (2004) 0.88
GABAergic neurons in rat nuclei of solitary tracts receive inhibitory-type synapses from amygdaloid efferents lacking detectable GABA-immunoreactivity. J Neurosci Res (1996) 0.86
Distribution and ultrastructural localization of GEC1 in the rat CNS. Neuroscience (2006) 0.85
A randomized controlled study of the effectiveness of intensive outpatient treatment for cocaine dependence. Psychiatr Serv (1998) 0.85
Serotonergic innervation and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral amygdaloid nuclei. Brain Struct Funct (2012) 0.85
Underreporting of cocaine use at posttreatment follow-up and the measurement of treatment effectiveness. J Nerv Ment Dis (1997) 0.84
Anatomical evidence for presynaptic modulation by the delta opioid receptor in the ventrolateral periaqueductal gray of the rat. J Comp Neurol (2001) 0.84
Projections from the periaqueductal gray to the rostromedial pericoerulear region and nucleus locus coeruleus: anatomic and physiologic studies. J Comp Neurol (1991) 0.83
Opiate agonist-induced re-distribution of Wntless, a mu-opioid receptor interacting protein, in rat striatal neurons. Exp Neurol (2011) 0.83
Gender differences and similarities in African-American crack cocaine abusers. J Nerv Ment Dis (1995) 0.83
Pretreatment dropouts: characteristics and outcomes. J Addict Dis (1997) 0.83
Periaqueductal gray neurons monosynaptically innervate extranuclear noradrenergic dendrites in the rat pericoerulear region. J Comp Neurol (2000) 0.83
alpha2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. Brain Res (1998) 0.82
Cocaine withdrawal-induced anxiety in females: impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment. J Neurosci Res (2010) 0.82
Analysis of synaptic inputs and targets of physiologically characterized neurons in rat frontal cortex: combined in vivo intracellular recording and immunolabeling. Synapse (1994) 0.82
Ultrastructural analysis of ventrolateral periaqueductal gray projections to the A7 catecholamine cell group. Neuroscience (2001) 0.81
Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure. Exp Neurol (2012) 0.81
Agonist-induced internalization of κ-opioid receptors in noradrenergic neurons of the rat locus coeruleus. J Chem Neuroanat (2010) 0.81
Dopamine-D1 and delta-opioid receptors co-exist in rat striatal neurons. Neurosci Lett (2006) 0.81
Direct targeting of peptidergic amygdalar neurons by noradrenergic afferents: linking stress-integrative circuitry. Brain Struct Funct (2013) 0.80
Does intensive outpatient cocaine treatment reduce AIDS risky behaviors? J Addict Dis (1998) 0.80
Opioid circuits originating from the nucleus paragigantocellularis and their potential role in opiate withdrawal. Brain Res (2002) 0.79
Coordinate regulation of noradrenergic and serotonergic brain regions by amygdalar neurons. J Chem Neuroanat (2013) 0.79
Randomized comparison of intensive outpatient vs. individual therapy for cocaine abusers. J Addict Dis (1997) 0.79
Ultrastructural evidence for prominent postsynaptic localization of alpha2C-adrenergic receptors in catecholaminergic dendrites in the rat nucleus locus coeruleus. J Comp Neurol (1998) 0.79
Long-term methadone maintenance treatment: some clinical examples. J Subst Abuse Treat (1993) 0.78
Cocaine users in medical practice: a five-year follow-up. Am J Drug Alcohol Abuse (1992) 0.78
Therapist/patient matching and early treatment dropout. J Addict Dis (1994) 0.77
Ultrastructural characterization of neurons recorded intracellularly in vivo and injected with lucifer yellow: advantages of immunogold-silver vs. immunoperoxidase labeling. Microsc Res Tech (1995) 0.77
Intracisternal rSV40 administration provides effective pan-CNS transgene expression. Gene Ther (2011) 0.77
Prediction of length of stay in an inpatient dual diagnosis unit. Gen Hosp Psychiatry (1995) 0.77
Characteristics of cocaine-addicted individuals who abuse their partners. J Subst Abuse Treat (1998) 0.76
Ultrastructural analysis of rat ventrolateral periaqueductal gray projections to the A5 cell group. Neuroscience (2012) 0.75
Outreach engagement efforts: are they worth the effort? Am J Drug Alcohol Abuse (1997) 0.75
Bone marrow-derived cells migrate to line the vessels of the CNS: opportunities for gene delivery to CNS vasculature. Neuroscience (2011) 0.75